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The therapeutic response rates of patients to donepezil vary from 20% to 60%, one of the reasons is their
genetic differences in donepezil-metabolizing enzymes, which directly inﬂuence liver metabolism.
However, the mechanism of donepezil metabolism and that of its enantiomers is unknown. This study
evaluated CYP2D6 polymorphisms to elucidate the stereoselective metabolism of donepezil and to
conﬁrm the association between the steady-state plasma concentrations of the pharmaco-effective S-
donepezil and the therapeutic responses of Han Chinese patients with Alzheimer's disease.
The in vitro study of the stereoselective metabolism demonstrated that CYP2D6 is the predominant
P450 enzyme that metabolizes donepezil and that different CYP2D6 alleles differentially affect donepezil
enantiomers metabolism. A total of 77 Han Chinese patients with Alzheimer's disease were recruited to
conﬁrm these results, by measuring their steady-state plasma concentrations of S-donepezil. The related
CYP2D6 genes were genotyped.
Plasma concentrations of S-donepezil (based on CYP2D6 polymorphisms) were signiﬁcantly associated
with therapeutic responses. This ﬁnding suggests that plasma concentrations of S-donepezil inﬂuence
therapeutic outcomes following treatment with donepezil in Han Chinese patients with Alzheimer's
disease. Therefore, determining a patient's steady-state plasma concentration of S-donepezil in combi-
nation with their CYP2D6 genotype might be useful for clinically monitoring the therapeutic efﬁcacy of
donepezil.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Donepezil (DNP) is a reversible cholinesterase inhibitor with a
high speciﬁcity for centrally active cholinesterases (1e4). Marketedtional Natural Science Foun-
hanghai Jiao Tong University
hina. Tel.: þ86 21 24058098;
rmacological Society.
. Production and hosting by Elseunder the name Aricept®, this drug is used in many countries for
the treatment of mild-to-moderate Alzheimer's disease (AD) (5, 6).
Patients have response rates to DNP that differ by up to 20%e60%
(7e11), this may be inﬂuenced by many factors, from both phar-
macokinetic and pharmacodynamic effects. Metabolism is one of
the major causes leading to the variability in clinical response of
DNP (12,13). It has been reported that 6-O-desmethyl DNP (6-ODD)
is the only active metabolite of DNP that inhibits acetyl cholines-
terase (AChE) as effectively as DNP itself (14e16). CYP2D6, CYP3A4,
CYP3A5 and CYP2C9 are thought to be involved in the metabolism
of DNP, but this has not yet been proven (17).
DNP has a chiral structure and exists as two enantiomers: S-
donepezil (S-DNP) and R-donepezil (R-DNP). These twovier B.V. This is an open access article under the CC BY-NC-ND license (http://
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AChE in vivo and in vitro, with S-DNP having a 2.2-fold higher af-
ﬁnity to AChE than R-DNP (18, 19). Thus, S-DNP is considered to be
the pharmaco-effective enantiomer of DNP. To our knowledge, only
one study has determined that patient plasma concentrations of
DNP exhibit stereoselectivity, but the mechanism of this property
has not been determined (20).
Plasma concentrations of DNP might serve as good biomarkers
for evaluating its effectiveness. Studies that have explored the
relationship between the plasma concentration of racemic DNP
and its therapeutic response have produced contradictory results
(5, 8, 21, 22). There are several potential explanations for these
differing results, including the following: [1] The pharmaco-
effective enantiomer S-DNP may be a more sensitive and accu-
rate blood biomarker for evaluating the clinical outcome of DNP.
[2] The main P450 enzymes and other mechanisms involved in the
metabolism of DNP and its two enantiomers are unknown. [3]
CYP2D6*10 is the most common mutant allele in Asians (8), with
37.9% of the Chinese population carrying the CYP2D6*1 variant and
51.3% carrying the CYP2D6*10 variant (23). Thus, variations in in-
dividual plasma concentrations may reﬂect CYP2D6 poly-
morphisms. To our knowledge, no prior study has focused on the
effects of individual variations in CYP2D6 alleles on the stereo-
selective metabolism and effectiveness of DNP. [4] Finally, the
results of in vitro experiments need to be conﬁrmed in AD patients
treated with DNP.
Based on the above-mentioned analysis, in this study, we
explored the stereoselective metabolism of DNP. Next, our in vitro
results were conﬁrmed in Chinese patients (n ¼ 77) by measuring
their steady-state plasma concentrations of S-DNP and racemic
DNP and genotyping the related CYP2D6 alleles. Associations be-
tween steady-state plasma concentrations of S-donepezil and
CYP2D6 polymorphisms were evaluated, as well as the therapeutic
responses of Han Chinese patients with Alzheimer's disease.
2. Materials and methods
2.1. Chemicals and reagents
Racemic DNP was obtained from the National Institute for the
Control of Pharmaceutical and Biological Products (Beijing, China).
S-DNP and R-DNP were separated and prepared by high-
performance liquid chromatography (HPLC), which are similar to
those in our previous study (20). D5-DNP was obtained from TLC
Pharma Chem (Vaughan, Ontario, Canada). 6-O-desmethyl DNP
was purchased from Toronto Research Chemicals Inc. (Toronto,
Canada). Methanol, acetonitrile, ammonium formate, and formic
acid (HPLC-grade) were purchased from Tedia Inc. (CA, USA). b
-Nicotinamide adenine dinucleotide phosphate (NADPH), glucose
6-phosphate, and glucose-6-phosphate dehydrogenase were pur-
chased from SigmaeAldrich (St. Louis, MO). Sulfaphenazole was
purchased from Dr. Ehrenstorfer Company (Germany). Quinidine
was purchased from J&K Scientiﬁc Ltd. (Sweden), and Ketoconazole
was purchased from the National Institute for the Control of
Pharmaceutical and Biological Products (Beijing, China). All other
chemicals and solvents were analytical grade and were purchased
from commercial sources.
2.2. Human liver microsomes and P450 recombinants
Pooled human liver microsomes (Mongolian; Lot No: SUBK)
were purchased from the Research Institute for Liver Diseases
(Shanghai, China). Five different human P450 recombinants,
CYP2D6*1/*1, CYP2D6*10/*10, CYP3A4, CYP3A5 and CYP2C9, were
purchased from Cypher Limited Company (UK). All human livermicrosomes and recombinants were frozen and stored at 80 C
until use.
2.3. Metabolism of DNP enantiomers in human liver microsomes
and P450 recombinants
S-DNP and R-DNP metabolism (ﬁnal concentration 0.5 mM) was
analyzed using human liver microsomal proteins and P450
recombinants in 0.1 M potassium phosphate buffer at pH 7.4 with
5.0 mM MgCl2 at 37 C in a ﬁnal incubation volume of 150 mL (20,
24). The reactions were initiated by adding the NADPH regenerat-
ing system. After incubation, the reactions were stopped by adding
450 mL of ice-cold acetonitrile containing an internal standard (D5-
DNP). The stabilities of the substrates were tested by incubating
them in the absence of the NADPH-regenerating system. The ki-
netics of the system were assessed using six different substrate
concentrations of R-DNP and S-DNP, ranging from 5 to 50 mM; the
reactions occurred within 90 min after a 5-min pre-incubation (20,
24). The concentrations and incubation times were chosen based
on preliminary experiments evaluating the length of time required
for the formation of 6-ODD. The incubation times were chosen such
that DNP remained stable and the P450 enzymes remained active,
and the duration of the experiment was suitable for detecting the
formation of metabolic products (data not shown). The linearity of
the rate of formation of the metabolite 6-ODDwas established with
respect to microsomal protein content and incubation time. The
samples were aliquoted and stored at 80 C until analyzed. All
reactions were performed in triplicate.
2.4. HPLC-MS/MS analytical procedures
The metabolite of DNP and 6-ODD was separated on an Agilent
1200 series liquid chromatograph (LC) and detected using an Agi-
lent 6410B tandem mass spectrometer (Agilent Technologies, CA,
USA). LC separation was performed on a Venusil C18 column
(50 mm  2.1 mm, 3.5 mM) after passage through a Zorbax SB-C18
pre-column (2.1 mm 12.5 mm, 5.0 mM). The details of the method
that was used to measure the plasma concentrations of DNP have
been previously established (20).
2.5. Kinetic data analysis
The results were expressed as the means ± S.D. The data were
ﬁtted to the MichaeliseMenten model to analyze the rates of for-
mation of DNP metabolites from DNP enantiomers and to estimate
enzyme kinetic parameters (GraphPad Software, Version 5.02). The
formation rates of 6-OD-DNP were ﬁtted to the MichaeliseMenten
kinetics with a one-enzyme kinetic model: V ¼ Vmax. [S]/Km þ [S],
where V is the velocity of the reaction at substrate concentration,
Vmax is the maximum velocity of each enzyme, and Km is the
substrate concentration at which the reaction velocity is 50% of
Vmax. Intrinsic clearance (Clin) was calculated as Clint ¼ Vmax/Km.
(25, 26).
2.6. Inhibition studies of DNP metabolite formation
Inhibition studies were performed to evaluate which P450 iso-
forms were involved in each metabolic pathway of DNP. P450
isoform-selective inhibitors were used to evaluate the formation of
6-ODD from DNP racemate and DNP enantiomers (25, 27, 28).
These included sulfaphenazole (10 mM) (CYP2C9), quinidine
(10 mM) (CYP2D6), and ketoconazole (1 mM) (CYP3A) (26). We used
a 90-min incubation time based on a preliminary experiment
conducted at 37 C with a 5-min pre-incubation. All of the incu-
bation conditions were similar to those described above.
Table 1
Kinetics parameters of 6-ODD from R- and S-DNP in human liver microsomes.
R-DNP S-DNP
Vmax 49.45 ± 11.21 28.64 ± 3.69
Km 154.70 ± 43.8 118.80 ± 20.28
Clint 0.32 ± 0.01 0.24 ± 0.02
Vm was expressed as pmol/min/mg protein, Km as mM, and Clint as Vmax/Km in ml/
min/mg protein. R- and S-DNP were incubated for 90 min at 37 C with 1 mg/ml
human liver microsomal proteins. The stability of the substrates was tested by
incubating them without the NADPH-regenerating system. System kinetic studies
were performed using six substrate concentrations, ranging from 5 to 50 mMof DNP.
The data shown are averages of triplicate experiments.
Fig. 1. Formation of 6-ODD from R-DNP(-) and S-DNP (C) during incubation of
human liver microsomes. S-DNP and R-DNP metabolism was analyzed using human
liver microsome proteins in 0.1 M potassium phosphate buffer at pH 7.4 with 5.0 mM
MgCl2 at 37 C in a ﬁnal volume of 150 mL. The reactions were initiated by adding the
NADPH regenerating system. After incubation, the reactions were stopped by adding
450 mL of ice-cold acetonitrile with an internal standard (D5-DNP). The reaction pro-
ceeded for 90 min after a 5-min pre-incubation for a preliminary test. The data shown
are averages of triplicate experiments.
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DNP enantiomers, related CYP2D6 gene polymorphisms and clinical
outcomes
2.7.1. Patients and study design
This studywasapprovedby the Ethics Committeeof Shanghai Jiao
Tong University Afﬁliated Sixth People's Hospital and complied with
the Declaration of Helsinki. All of the patients or their legal guardians
provided written informed consent. A total of 77 Han Chinese par-
ticipants (46 men and 31 women; age 65e94 years; mean age
81.7±6.7years),whowerepatients at theDepartmentofGeriatrics at
Shanghai Jiao Tong University Afﬁliated Sixth People's Hospital be-
tween September 2013 and October 2014, participated in the study.
The patientswere selected based upon the following criteria: [1] Han
Chinese, age65years; [2] diagnosedwithmild-to-moderateAD(29,
30); [3] administered a stable daily dose of DNP for at least 3months.
The exclusion criteria included the following: [1] non-AD dementia;
[2] taking a combination of other drugs mainly metabolized by
CYP2D6; or [3] taking other cognition-enhancing drugs.
All patients were started on DNP therapy at 5e10 mg/day (70
patients at 5 mg/day, 7 patients at 10 mg/day). The Mini Mental
State Examination (MMSE) was used to evaluate cognitive impair-
ment in the patients; the MMSE was used twice, once before DNP
treatment and once after a DNP treatment lasting for at least 3
months (31). Minimum steady-state blood samples were collected
from the patients before the next dose was administered. After a
follow-up period of at least 3 months, patients who showed no
declines in MMSE scores were deﬁned as responders (32).
2.7.2. Genetic analysis of the CYP2D6 gene
Peripheral blood was collected into EDTA Vacutainer tubes and
stored at 80 C until analysis. CYP2D6 was genotyped using PCR-
LDR (ligase detection reaction) technologies. Genomic DNA was
extracted from the peripheral blood samples using an AxyPrep-96
DNA blood kit (AXYGEN, USA). CYP2D6 alleles were identiﬁed by
allele-speciﬁc PCR technology (31). CYP2D6 gene polymorphisms
were analyzed by examining rs1065852. The sequences were
analyzed using an ABI PRISM 3100 DNA Sequencer (Applied Bio-
systems, CA, USA).
2.7.3. Separation and quantitation of R-DNP and S-DNP in patient
plasma
DNP enantiomers were separated and analyzed by LC-MS/MS;
D5-DNP was used as an internal standard (20). The detailed
methods of the detection procedures were the same as those
established in our previous study (20). The measured plasma
concentrations were corrected for each patient according to the
dose (Cp/dose) (33).
2.7.4. Statistical methods
Data analysis was performed using SPSS statistical software
(standard version 17.0; SPSS Inc, Chicago, U.S.). p-values < 0.05 indi-
cated statistical signiﬁcance. The results were expressed as the
mean ± SD. KruskaleWallis analysis was used to analyze differences
betweengenotypes, and theManneWhitney testwasused to analyze
differences between two groups. Thec2 testwas used to compare the
rates of responders possessing different genotypes of CYP2D6.
3. Results
3.1. Metabolism of DNP enantiomers in human liver microsomes
DNP enantiomer metabolism was analyzed in human liver mi-
crosomes, and O-demethylation kinetics were studied under
optimal microsomal protein concentration (1 mg/ml) andincubation time (90 min), which was based on preliminary exper-
iments (27). The apparent kinetic characteristics for the formation
of 6-ODD metabolites from each enantiomer are summarized in
Table 1. The data indicated that the Vmax for the formation of 6-OD-
DNP from R- DNP was higher than S-DNP (49.45 ± 11.21 versus
28.64 ± 3.69), t the formation rates of the metabolite from R-DNP
were signiﬁcantly higher than it from S-DNP (Fig. 1). The Km values
were 154.7 ± 43.8 for R- DNP and 118.8 ± 20.28 for S-DNP. There-
fore, the Vmax/Kmvalue for R-DNPwas1.33-fold greater than that of
S-DNP. The data indicated that racemic DNP undergoes slight
stereoselectivity when being metabolized in vitro.
3.2. Chemical inhibition studies of DNP metabolism
A P450 isoform-selective inhibition study was performed to
evaluate the P450 isoforms involved in the stereoselective meta-
bolism of DNP in human liver microsomes (Table 2).
Three inhibitors were used. Quinidine, a CYP2D6-selective in-
hibitor, inhibited the formation of the DNP O-demethylation
metabolite 6-ODD from both isomers. Ketoconazole, a CYP3A-
selective inhibitor, and sulfaphenazole, a CYP2C9-selective inhibi-
tor, both inhibited themetabolism of R-DNP and S-DNP. Data shown
in Table 2. Rates of formation of 6-ODD decreased dependented on
concentrations of inhibitors. Treated with 10 mM sulfaphenazole,
compared to the controls, the rate of 6-ODD formation from R-DNP
Table 2
Stereoselective inhibition of known P450 isoform-selective inhibitors on the for-
mation of 6-ODD from R- and S-DNP in human liver microsomal incubations.
Quinidine Sulfaphenazole Ketoconazole
R-DNP 34.08 ± 0.62 67.74 ± 6.89 78.21 ± 2.05
S-DNP 34.21 ± 1.98 80.39 ± 1.30 80.11 ± 7.45
Racemate 31.02 ± 0.71 64.73 ± 2.98 67.98 ± 2.38
The rates of formation of 6-ODD from DNP racemate (5 mM) or DNP enantiomers
(5 mM) were analyzed with or without P450 isoform-selective inhibitors at 37 C for
90 min after a 5-min pre-incubation. The P450 isoform-selective inhibitors were:-
sulfaphenazole (10 mM) (CYP2C9), Quinidine (10 mM) (CYP2D6), and ketoconazole
(1 mM) (CYP3A). The data shown are averages of triplicate experiments.
Table 3
Kinetics parameters of 6-ODD from R- and S-DNP from the cDNA-expressed P450s.
CYP2D6*1/*1 CYP2D6*10/*10 CYP 3A4 CYP 2C9
R-DNP
Vmax 304.4 ± 45.86 135.5 ± 22.28 11.23 ± 10.49 11.11 ± 2.45
Km 34.33 ± 9.87 33.92 ± 10.89 53.07 ± 8.26 59.08 ± 20.32
Clint 8.87 ± 0.08 4 ± 0.38 2.12 ± 0.05 0.19 ± 0.02
S-DNP
Vmax 230.6 ± 35.51 125.4 ± 28.06 44.15 ± 11.1 8.2 ± 2.99
Km 27.72 ± 8.93 47.66 ± 18.04 89.2 ± 31.84 79.09 ± 41.58
Clint 8.32 ± 1.91 2.63 ± 0.13 0.49 ± 0.02 0.1 ± 0.01
p Value 0.51 0.05 0.05 0.04*
Vm is expressed as pmol/min/mg protein, Km as uM, and Clint as Vmax/Km(ml/min/
mg protein). The metabolism of S-DNP and R-DNP (ﬁnal concentration 0.5 mM) was
conducted using cDNA-expressed P450 isoforms in potassium phosphate buffer pH
7.4 with MgCl2 at 37 C, in a ﬁnal incubation volume of 150 mL. The reactions were
initiated by adding the NADPH regenerating system. After incubation, the reactions
were stopped by adding 450 mL of ice-cold acetonitrile with internal standard (D5-
DNP). The stability of the substrates was tested by incubating them without the
NADPH-regenerating system. System kinetic studies were performed using six
substrate concentrations, ranging from 5 to 50 mMof R-DNP and S-DNP; the reaction
time was 60e90 min after a 5-min pre-incubation for preliminary tests. The line-
arity of the metabolites and the rate of formation of 6-ODD was established with
respect to themicrosomal protein and incubation time. The data shown are averages
of triplicate experiments.
*p < 0.05.
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S-DNP decreased to 80.39%. The formation of 6-ODD from R- and S-
DNP was also inhibited by quinidine and ketoconazole, suggesting
that the formation of stereoselective O-demethylation metabolites
from both DNP enantiomers was mediated by more than one
enzyme and that therewas a stereoselective inhibitory effect on the
formation of 6-ODD. The formation of 6-ODD was largely inhibited
by the CYP2D6-selective inhibitor quinidine and was slightly
inhibited by the CYP3A-selective inhibitor ketoconazole. Therefore,
we concluded that CYP2D6, CYP3A, and CYP2C9 each contribute to
the stereoselective metabolism of DNP in human liver microsomes.
3.3. Selective metabolism of DNP by P450 recombinants
The formation of O-demethylation metabolites from DNP en-
antiomers was also studied using P450 recombinants (Table 3). WeTable 4
Demographic and clinical characteristics of the 77 Han Chinese patients with AD after 3
Responders (44)
Age, years (mean ± SD) 81.3 ± 6.8
Gender, female (%) (18/44) 40.91%
MMSE scores at baseline 20.84 ± 4.65
MMSE scores at steady-state 22.86 ± 4.48
Mean/Range for change of MMSE scoresa 1.86 (0e6)
A total of 77 patients with a diagnosis of mild to moderate Alzheimer's disease were tre
*p < 0.05.
a The data were expressed as the difference between the last and the ﬁrst MMSE scorexamined the enzyme kinetic parameters of the formation of the
DNP O-demethylation metabolite 6-ODD from R- and S-DNP upon
incubation with the P450 recombinants CYP2D6*1/*1, CYP2D6*1/
*10, CYP3A4, and CYP2C9. The formation of 6-ODD was catalyzed
most efﬁciently by CYP2D6*1/*1; the Clint value corresponding to
O-demethylation by CYP2D6*1/*1 was similar for both R- and S-
DNP (8.87 versus 8.32 for CYP2D6*1/*1) due to their similar Vmax
and Km values (p ¼ 0.513). CYP3A4 did not affect the production of
the 6-ODD metabolite from S-DNP, but it did show a relatively
strong effect on the production of 6-ODD from R-DNP. The Clint
value for the formation of 6-ODD by CYP3A4 was 4.32-fold higher
for R-DNP than for S-DNP, which indicates the stereoselectivity of
this metabolism (p ¼ 0.05). CYP2D6*10/*10 also exhibits a slight
stereoselectivity in the formation of 6-ODD from R- and S-DNP
(Clint: 4.00 versus 2.63) (p ¼ 0.05). The metabolic activity of
CYP2C9 showed the lowest Clint value, and the Clint value corre-
sponding to O-demethylation by CYP2C9 was 1.9-fold higher for R-
DNP than for S-DNP (0.19 versus 0.1 for CYP2C9) (p ¼ 0.04), which
showed the slight stereoselectivity of CYP2C9. CYP3A5-mediated
metabolism of DNP was not observed (data not shown).
This indicates that CYP2D6 is the major P450 enzyme that
contributes to DNP metabolism.
CYP2D6*1/*1 and CYP2D6*10/*10 produced different effects on
the metabolism of R- and S-DNP. All 4 enzymes demonstrated
selectivity during R- and S-DNP metabolism.
3.4. Relationships between the steady-state plasma concentrations/
dose of S-DNP, the related CYP2D6 gene polymorphism and
therapeutic response
3.4.1. Characteristics of the enrolled participants
A total of 77 Han Chinese participants (age 60e94 years, mean
age 82 ± 6.7 years) were enrolled. The scores of their 1st MMSE
were all in the range of 10e29 with a mean of 21.64 ± 4.94, and the
scores of their 2nd MMSE were all in the range of 10e29 with a
mean of 20.81 ± 5.64. At the 3e6 month follow-up, 44 patients
were found to be responders (57.1%), whereas 33 were found to be
nonresponders (42.9%). The demographic and clinical characteris-
tics of the 77 included Han Chinese patients are summarized in
Table 4. No signiﬁcant differences were found between the ages of
the responders and the nonresponders (p ¼ 0.642). The sex ratio
was also not signiﬁcantly different between the 2 groups
(p ¼ 0.893). The changes in MMSE scores are also shown in Table 4.
3.5. Correlation between the steady-state plasma concentration/
dose of DNP/S-DNP and therapeutic response
The Cp/dose of racemic DNP in responders (8.37 ± 3.36 ng/ml/
mg) was higher than that in nonresponders (7.10 ± 2.79 ng/ml/mg),
but the differences did not reach statistical signiﬁcance (p > 0.05)
(Fig. 2A). The Cp/dose of S-DNP in responders (5.47 ± 2.94 ng/ml/
mg) was signiﬁcantly higher than that in nonresponders
(4.02 ± 1.66 ng/ml/mg) (p¼ 0.043) (Fig. 2B). These ﬁndings indicatemonths of DNP therapy.
Nonresponders (33) p-Value
82.1 ± 6.4 0.642
(13/33) 39.39% 0.893
22.70 ± 5.19 0.045*
18.06 ± 5.51 0.000
4.64 (1 to 18)
ated with DNP (70 patients with 5 mg/day, 7 patients with 10 mg/day).
e.
Fig. 2. (A) Relationship between Cp/dose values of racemic DNP and therapeutic responses in AD patients. (B) Correlation between Cp/dose values of S-DNP and therapeutic re-
sponses in AD patients. A total of 77 Chinese patients with diagnoses of mild-to-moderate Alzheimer's disease were treated with DNP (70 patients with 5 mg/day, 7 patients with
10 mg/day). Their minimum plasma steady-state concentrations/doses of racemic DNP and effective S-DNP were measured. The measured plasma concentrations were corrected for
dose (Cp/Dose) and expressed as ng/ml/mg [33]. Differences between the last and the ﬁrst MMSE scores were used as an index of therapeutic responses to DNP. Data were presented
as average ± standard deviation. *p < 0.05.
Fig. 3. Relationship between CYP2D6 genotype and changes in MMSE scores in re-
sponders. A total of 44 Han Chinese patients with Alzheimer's disease who were
administered DNP treatment for at least 3 months were enrolled were deﬁned as re-
sponders; three CYP2D6 alleles were genotyped. Data were presented as
average ± standard deviation. *p < 0.05.
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following DNP treatment.
3.6. Correlation between CYP2D6 alleles and the therapeutic
responses of responders in patients
The changes of MMSE were assessed in responders. The changes
in MMSE score in responders with the CYP2D6*1/*1 allele were
slightly lower than those in responderswith theCYP2D6*10/*10 allele
(median: 2.20 versus2.29, respectively; p¼ 0.863), andCYP2D6*10/
*10 group showed the best clinical responses to treatment in three
groups. The responders with the CYP2D6*1/*10 allele showed the
worst clinical responses,whichwere signiﬁcantly lower than those of
the responderswith theCYP2D6*1/*1allele (median:0.92versus.2.20,
respectively; p ¼ 0.01), and those of the responders with the
CYP2D6*10/*10 allele (median: 0.92 versus 2.29, respectively;
p ¼ 0.03), as assessed by changes in MMSE scores (Fig. 3)
3.7. Correlation between CYP2D6 alleles and steady-state plasma
concentrations/dose of DNP/S-DNP
The Cp/dose of racemic DNP of the CYP2D6*10/*10 groupwas the
highest (8.72± 3.46 ng/ml/mg), followed by that of the CYP2D6*1/*1
group (7.33 ± 2.48 ng/ml/mg) and the CYP 2D6*1/*10 group, which
was the lowest (7.15 ± 2.97 ng/ml/mg). However, no signiﬁcant
differences were observed between the Cp/dose ratios of racemic
DNP between the three CYP2D6 genotypes (p > 0.05) (Fig. 4A). The
Cp/dose of S-DNP was the highest in the CYP2D6*10/*10 group
(5.78 ± 2.94 ng/ml/mg), followed by that in the CYP2D6*1/*1 group
(4.24 ± 1.34 ng/ml/mg) and the CYP2D6*1/*10 group, which was the
lowest (3.97 ± 1.62 ng/ml/mg). Signiﬁcant differences in the S-DNP
Cp/dose values were demonstrated between the three CYP2D6 ge-
notypes (p ¼ 0.007) (Fig. 4B). While there is no signiﬁcant correla-
tion between CYP2D6 alleles and steady-state plasma
concentration/dose ratio of R-DNP (data not shown).
4. Discussion
Considerable interindividual variability has been shown in
clinical therapeutic responses to DNP, with responder rates as lowas 20e60% (8, 34e37). In our study, the response rate was 57.1%. A
plasma concentrationeresponse effect has been reported for DNP,
such that differences in therapeutic outcomes could be related to
some extent to genetic polymorphisms that affect the metabolism
or transport of DNP.
S-DNP has been reported to be the pharmaco-effective enan-
tiomer of DNP (18). Thus, evaluating the stereoselective meta-
bolism of DNP in combination with assessing the genetic
backgrounds of patients and their therapeutic responses might
increase the accuracy of evaluating DNP efﬁcacy in clinical practice.
Previous studies indicated that O- demethylation is the main route
Fig. 4. (A) Relationship between Cp/dose of racemic DNP and three CYP2D6 alleles: CYP2D6*1/*1, CYP2D6*1/*10 and CYP2D6*10/*10. (B) Correlation between Cp/dose of S-DNP and
three CYP2D6 genotypes: CYP2D6*1/*1, CYP2D6*1/*10, and CYP2D6*10/*10. Cp/dose was expressed as ng/ml/mg. Horizontal bars represent the median values. **p < 0.01.
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pharmacological activity similar to DNP, which plays most impor-
tant role in biological activity of DNP (6, 38). Second, the disposition
of active 6-ODD and DNP is different, which results in their
different roles in pharmacological activity of DNP (38). Thus in this
study, we chose the main route and the most important active
metabolite 6-ODD to explore responsible enzymes for the meta-
bolism of donepezil. We found that CYP2D6 polymorphisms play
important roles in the metabolism of DNP enantiomers. CYP3A4
plays a minor role in DNP pharmacokinetics (Table 3) the clint of
CYP2D6 for DNP is extremely high compared with that of CYP3A4,
maybe it is one of the reasons for clinic studies which indicates
CYP3A4 and CYP3A5 polymorphisms are unlikely to inﬂuence
donepezil metabolism and/or clinical outcome (33). To the best of
our knowledge, this is the ﬁrst study on the stereoselective meta-
bolism of DNP.
Patients with the CYP2D6*10/*10 genotype showed the best
clinical responses to treatment. This may be associated with cyto-
chrome P450 2D6 polymorphisms in different ethnic groups
(39e41). In this study, we found that different CYP2D6 genotypes
inﬂuence the steady-state plasma concentrations of DNP in Chinese
AD patients (Fig. 3), whichmay result fromDNP being processed by
potentially different metabolic pathways in the liver. Studying the
correlation between CYP2D6 alleles and Cp/dose of S-DNP
conﬁrmed these results; however, they still must be conﬁrmed by
larger studies.
A wide standard deviation in the steady-state plasma concen-
trations of pharmacologically effective S-DNP was measured in our
subjects. This may be due to a large extent to variations in CYP2D6
alleles in Han Chinese patients with AD (23). Because DNP exhibits
linear pharmacokinetics, the measured plasma concentrations
were corrected for DNP dose (Cp/Dose) (21, 33).
Previous studies in Caucasians have primarily focused on the
CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5 and CYP2D6*6 geno-
types. Subjects carrying two defective alleles (CYP2D6*3, *4, *5 or
*6) were classiﬁed as PM; people with one defective allele, as
heterozygous EM; people with two CYP2D6*1 alleles, as homozy-
gous EM. People carrying a duplicated/multi-duplicated allele
together with CYP2D6*1 were classiﬁed as UM (22). Focusing on
the correlation between CYP2D6 genotype and DNP efﬁcacy, most
of these studies showed that CYP2D6 polymorphisms signiﬁcantly
affected clinical responses in Caucasians; Emswere also shown to
have signiﬁcantly larger changes in MMSE scores (2, 33, 40, 42).These results are consistent with a previous study that we con-
ducted in an Asian population (8). Additionally, the current study
conﬁrmed these results in Chinese patients and found that the
CYP2D6 polymorphism does play a role in the therapeutic re-
sponses of Chinese AD patients.
These studies also focused on examining the relationships
between CYP2D6 genotypes and DNP plasma concentrations.
Although different CYP2D6 genotypes have been shown to in-
ﬂuence the plasma concentrations of DNP (43, 44), to our
knowledge, only three previous studies have investigated the
relationships between CYP2D6 genotypes and DNP pharmacoki-
netics (16, 21, 22). One study on an Italian population reported
lower plasma levels of DNP in homEMs than in hetEMs, while
Ums had lower plasma concentrations than EMs (22). However,
these differences in plasma concentrations did not reach statis-
tical signiﬁcance. Another study conducted in Switzerland
conﬁrmed the inﬂuence of the CYP2D6 PM and UM phenotypes
on DNP Clint. In a third study that evaluated 70 Taiwanese pa-
tients with AD, it was suggested that higher plasma concentra-
tions of DNP were signiﬁcantly associated with better therapeutic
responses in long-term memory (21). We consider the main
reasons for these different results to include the following: 1)
these studies were conducted in different ethnic groups, and 2)
they investigated concentrations of racemic DNP as opposed to S-
DNP, which is the pharmaco-effective enantiomer of DNP. This
may have resulted from: the racemic-DNP encompassing the
differences of the metabolism of each enantiomer in the liver,
including the effective S-enantiomer, such that the Cp/dose of
racemic DNP could not use to evaluate the clinical outcome of the
drug. Our ﬁndings suggest that steady-state plasma concentra-
tions of the S-enantiomer could be used as blood biomarkers to
evaluate therapeutic responses to DNP treatment in Han Chinese
patients with AD in the future.
Several studies have also focused on the CYP3A4 and CYP3A5
alleles in Caucasians and have suggested that CYP3A4 and CYP3A5
allele variants do not play pivotal roles in the variability of DNP
metabolism (16, 22, 33). However, other researchers have
concluded that CYP3A4/5 alleles do play roles in the metabolism of
DNP (41). However, none of them conducted the in vitro study. Our
study identiﬁed that CYP3A4 and CYP3A5 play minor roles in the
metabolism of DNP. Previous data have shown that mutations in
the CYP3A4, CYP3A5 and CYP2C9 alleles are nearly nonexistent in
Han Chinese (45, 46). Thus, we did not analyze the effects of the
J. Lu et al. / Journal of Pharmacological Sciences 129 (2015) 188e195194CYP3A4/5 alleles or the CYP2C9 allele polymorphism on the clinical
outcomes of DNP treatment in Han Chinese patients.
Our study presents several strengths. First, this is the ﬁrst study
to explore the stereoselective metabolism of DNP. We focused on
Cp/dose of S-DNP but not that of racemic DNP clinically. Second, for
many central nervous system (CNS) drugs, it has been shown that
drug concentrations in the brain correlatewith drug concentrations
in the blood (47). The latter can also be used to estimate drug
clearance and bioavailability. Monitoring plasma concentrations of
drugs enables the identiﬁcation of many factors that may inﬂuence
patient therapeutic responses. This study reveals another approach
for evaluating the efﬁcacies of CNS drugs. The plasma concentration
of a drug is easier to obtain non-invasively compared to CSF sam-
ples. Third, we measured the minimum valley steady-state plasma
concentration of DNP instead of only reporting the daily dosage.
Thus, measuring the plasma concentrations of DNP mostly re-
ﬂected the amount that remained after its absorption and meta-
bolism in vivo (21, 22).
The main limitation of our study is the need for further studies
on the use of steady-state plasma concentrations of S-DNP as po-
tential biomarkers, which relies on population pharmacokinetics
models. Thus, our study would have had to evaluate population
pharmacokinetics models of S-DNP plasma concentrations that
includedmultiple individual factors, such as sex, age, and gender, to
make the steady-state plasma concentration of S-DNP a more
sensitive and reliable biomarker. Finally, our results must be
conﬁrmed by larger studies.
In neurodegenerative diseases such as Alzheimer's disease, drug
efﬁcacy is best evaluated during the early stages of treatment (47,
48). However, no effective and convenient blood biomarkers are
currently available to evaluate the efﬁcacy of DNP in the clinical
setting, particularly in the early stages of treatment. It is expected
that the steady-state plasma concentrations of S-DNP in relation to
patient CYP2D6 genotypes could serve as effective blood bio-
markers for evaluating the efﬁcacy of DNP treatment in the near
future.
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